Phase I study of zevalin (90Y-ibritumomab tiuxetan) in Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma)
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
- Indications Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 08 Jan 2013 Biomarkers information updated
- 13 Jul 2007 New trial record.